GET DAILY SIGNALSKura Oncology (KURA) Readies Q3 2026 Earnings as KOMZIFTI Launch Takes Shape
Key Takeaways
- Kura Oncology (NASDAQ: KURA) is scheduled to report third-quarter 2026 results after the market close on November 10, 2026, with a conference call at 4:30 p.m. ET.
- Wall Street consensus points to a net loss of roughly $0.82 per share on revenue of approximately $24.9 million, versus a loss of $0.85 per share on $20.75 million in revenue a year ago.
- Investors will focus on the commercial trajectory of KOMZIFTI (ziftomenib), Kura's first approved drug for NPM1-mutated acute myeloid leukemia (AML), after it generated $9.1 million in net product sales in its first full quarter.
- The company held approximately $519 million in cash at the end of the second quarter, which management has said funds operations into 2028.
- Kura has beaten consensus EPS estimates in two of its last six quarters, including a $0.11-per-share beat in Q2 2026.
- For more on KURA, you can explore additional pages covering Major News, Today's Price Move, Price Targets, and Forecasts.
- To discover more timely trading ideas across the market, explore Trending AI Robots.
Why This Earnings Report Matters
Kura Oncology's third-quarter report marks another checkpoint in its transition from a clinical-stage developer to a commercial-stage precision oncology company. The launch of KOMZIFTI, which received U.S. Food and Drug Administration (FDA) approval in November 2025, is now the company's central revenue driver, and each quarter offers fresh evidence of how quickly the therapy is reaching newly diagnosed patients with NPM1-mutated AML. Beyond commercial execution, investors are watching research and development (R&D) spending, Kyowa Kirin collaboration revenue, and pipeline progress, including Phase 3 trial enrollment. With the stock trading well below its 52-week high, this report will help clarify whether the company's operating momentum is keeping pace with its long-term growth story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Analysts Are Expecting
Analysts expect Kura Oncology to report a net loss of approximately $0.82 per share for the third quarter of 2026, with revenue consensus near $24.9 million. Estimates range from a loss of about $0.81 to $0.84 per share on revenue of roughly $22 million to $25 million. These figures compare with a year-ago loss of $0.85 per share on $20.75 million in revenue. In the prior quarter, Kura posted a loss of $0.77 per share, beating the $0.88 consensus loss, on revenue of $20.87 million, which also exceeded expectations. Historically, the company has beaten EPS estimates in two of its last six quarters, and the stock has shown modest post-earnings moves in recent periods.
Market Sentiment Ahead of the Print
Sentiment heading into the report remains cautious. Kura's shares have traded substantially below their 52-week high, reflecting broader pressure on biotechnology valuations and uncertainty about the pace of KOMZIFTI's commercial ramp. The options market implies a meaningful one-day move around the print, underscoring elevated event risk. Key factors that could sway the reaction include the rate of new patient starts, any update on 2026 collaboration revenue guidance, and commentary on operating expense discipline. A beat on revenue and reassuring guidance could support the stock, while signs of slowing launch traction or rising cash burn could weigh on sentiment.
What to Watch Going Forward
Following the report, investors should watch several forward-looking indicators tied to KOMZIFTI's commercial execution. Quarterly net product sales and new patient starts will be the clearest signals of demand, and management commentary on reimbursement and market access could shape expectations for the remainder of 2026.
On the clinical side, enrollment progress in the KOMET-017 Phase 3 program and upcoming data readouts, including initial ziftomenib-FLT3 inhibitor combination data expected at ASH 2026, represent important catalysts. The company has also indicated plans to advance darlifarnib, its farnesyl transferase inhibitor, in pancreatic cancer studies.
Cost discipline remains another area of focus. As the commercial organization scales alongside ongoing R&D programs, investors will be watching whether operating expenses rise in line with guidance. With roughly $519 million in cash, Kura's runway into 2028 provides a buffer, but the trajectory of quarterly cash burn will remain a central concern as the company balances commercial investment with pipeline development.
Integrating AI Tools Into My Research Process
In my analysis of names like KURA, I find it helpful to run quick scans with Tickeron’s AI Screener to compare technical patterns, fundamentals, and volatility against peers. The tool lets me filter by industry, market cap, and performance metrics, which often surfaces context I might otherwise miss when preparing for events like earnings. It has become a regular part of how I cross-check ideas before the numbers come out.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KURA in upward trend: price may jump up because it broke its lower Bollinger Band on November 04, 2026
KURA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 43 cases where KURA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KURA's RSI Oscillator exited the oversold zone, 29 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where KURA advanced for three days, in 211 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KURA as a result. In 70 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for KURA turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for KURA entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. KURA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.354) is normal, around the industry mean (3.498). P/E Ratio (-2.157) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.821) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of biopharmaceutical services
Industry Biotechnology
Advertisement